drugset / Trial / NCT07307534

Nevus Removal vs. Conservative Treatment in Halo Nevus With Vitiligo: A Randomized Study

NCT07307534

Not yet recruiting 60 enrolled Xijing Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

This clinical trial aims to compare the efficacy and safety of central nevus removal versus conservative treatment in patients with halo nevus accompanied by non-segmental vitiligo. It is a single-center, prospective, randomized controlled trial involving 60 participants aged 6 to 45 years, who will be randomly assigned to either the nevus removal group or the conservative treatment group. The removal group will undergo surgical or laser excision of the central nevus followed by medication, while the conservative group will receive medication only. Both groups will be followed for 6 months. Outcomes include repigmentation assessment using vitiligo scoring indices, quality of life measures, and serial serum cytokine profiling. The study seeks to provide high-level evidence to guide clinical management of halo nevus with vitiligo. Key points: 1. For patients with halo nevus accompanied by non-segmental vitiligo. 2. For patients aged 6 to 45 years. 3. Compares nevus excision and conservative treatment. 4. Follows participants for 6 months. 5. Focuses on effectiveness and safety.

Timeline

Start
2026-01-20
Primary completion
2027-10-01
Completion
2027-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Prednisone Other / unclassified 0.3 mg/kg Oral
Subject Tacrolimus Small molecule 0.1 % Topical

Indications